The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients

作者: X. Huang , Q. Wang , S. Jiang , W. Chen , C. Zeng

DOI: 10.1093/CKJ/SFU117

关键词:

摘要: Background. Few data are available on the clinical features and outcomes of Chinese patients with systemic immunoglobulin light-chain (AL) amyloidosis. The aim this study is to reveal picture risk factors disease progression in a large cohort AL Methods. Patients Jinling Hospital amyloidosis registry from 2003 2011 were studied. laboratory information collected first presentation death or until last follow-up. patients’ survival renal analyzed, relationships between parameters also assessed. Results. A total 231 enrolled study, all studied had involvement. One hundred fifty-three (66.2%) male, median age at diagnosis was 56 years. 198 (85.7%) cases λ-type. forty-seven (63.6%) presented as nephrotic syndrome (NS), 25% insufficiency diagnosis. Liver involvement NS appeared be more common κ-type amyloidosis, impairment severe time 36.3 months, 1-, 2-, 3- 5-year cumulative rates 67, 53, 48 35%, respectively. Multivariate COX analysis showed that age, hepatic heart can significantly influence these patients. remained dialysis free 50 months. percentage 1, 2, 3 5 years 78, 69, 62 37%, serum creatinine hypotension important failure. Conclusion. λ-Type most dominant type poor. included involvement, function. high level associated poor outcome.

参考文章(22)
Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Immunoglobulin light chain amyloidosis and the kidney Kidney International. ,vol. 61, pp. 1- 9 ,(2002) , 10.1046/J.1523-1755.2002.00085.X
Melo Beirão, Eduarda Matos, Idalina Beirâo, Paulo Pinho E. Costa, Paulo Torres, Anticipation of presbyopia in Portuguese familial amyloidosis ATTR V30M. Amyloid. ,vol. 18, pp. 92- 97 ,(2011) , 10.3109/13506129.2011.576719
Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Nelson Leung, Steve R. Zeldenrust, Francis K. Buadi, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis Mayo Clinic Proceedings. ,vol. 83, pp. 297- 303 ,(2008) , 10.4065/83.3.297
E. Kastritis, M. A. Dimopoulos, Prognosis and risk assessment in AL amyloidosis – state of the art Amyloid. ,vol. 18, pp. 89- 91 ,(2011) , 10.3109/13506129.2011.574354032
Shaji Kumar, Angela Dispenzieri, Jerry A. Katzmann, Dirk R. Larson, Colin L. Colby, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Nelson Leung, Steve R. Zeldenrust, Marina Ramirez-Alvarado, Raynell J. Clark, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features Blood. ,vol. 116, pp. 5126- 5129 ,(2008) , 10.1182/BLOOD-2010-06-290668
Morie A. Gertz, Steven R. Zeldenrust, Treatment of immunoglobulin light chain amyloidosis Current Hematologic Malignancy Reports. ,vol. 4, pp. 91- 98 ,(2009) , 10.1007/S11899-009-0013-6
P. Russo, G. Palladini, A. Foli, L. Zenone Bragotti, P. Milani, M. Nuvolone, L. Obici, V. Perfetti, S. Brugnatelli, R. Invernizzi, G. Merlini, Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid. ,vol. 18, pp. 92- 93 ,(2011) , 10.3109/13506129.2011.574354033
Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo, Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of Blood and Marrow Transplantation. ,vol. 14, pp. 6- 11 ,(2008) , 10.1016/J.BBMT.2007.10.026
Miguel A. Park, Paul S. Mueller, Robert A. Kyle, Dirk R. Larson, Matthew F. Plevak, Morie A. Gertz, Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients Medicine. ,vol. 82, pp. 291- 298 ,(2003) , 10.1097/01.MD.0000091183.93122.C7
Morie A. Gertz, Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment American Journal of Hematology. ,vol. 88, pp. 416- 425 ,(2012) , 10.1002/AJH.25819